Clinical Trials Logo
  1. Home
  2. Dermatomyositis
  3. NCT04486261

High-intensity Strength Training in Myositis — HI-STIM  

Dermatomyositis Clinical Trial

Official title:
High-intensity Strength Training in Patients With Idiopathic Inflammatory Myopathies: Changes in Quality of Life, Muscle Strength, Function and Myocellular Parameters

Clinical Trial Summary

This study evaluates the effects of a high-intensity strength training in patients with myositis with the primary outcome being quality of life (SF-36). The study is designed as a parallel group randomised controlled trial with an intervention group and a control group.

Clinical Trial Description

Overall aim: To investigate the effect of high-intensity strength training on quality of life, muscle strength, physical function, and disease activity in patients with myositis Study design: 60 myositis patients will be included in a 16-week high-intensity strength training study. Patients will be randomly allocated into 2 groups (strength training and control) in a 1:1 ratio. User involvement: Myositis patients has been recruited to a patient advisory board. The advisory board's objective is to give patient-oriented project feedback, thus improving the overall research project. Intervention: Two training session per week for 16 weeks. Sessions consists of 3 sets of each exercise corresponding to 10 RM. Training progression will be accounted for and training loads will be evaluated weekly. The training protocol will be a full-body protocol, i.e. all major muscle groups will be engaged during each training session. Outcomes: The primary outcome is the Physical Component Summary Measure from the quality of life questionnaire (SF-36). Secondary outcomes include strength measures, functional tests, disease activity measures, questionnaires (e.g. International physical activity questionnaire), DEXA whole body scans, blood samples and muscle biopsies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04486261
Study type Interventional
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase N/A
Start date August 30, 2021
Completion date January 1, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05833711 - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy Phase 2
Completed NCT01906372 - Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Phase 2
Completed NCT01813617 - Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Completed NCT00004357 - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Phase 2
Recruiting NCT05832034 - Add-on Intravenous Immunoglobulins in Early Myositis Phase 2
Recruiting NCT05979441 - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Phase 3
Not yet recruiting NCT05027152 - Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties N/A
Active, not recruiting NCT04723303 - Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) Early Phase 1
Completed NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT05437263 - A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Phase 3
Active, not recruiting NCT04044690 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) Phase 3
Recruiting NCT05523167 - A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Phase 2/Phase 3
Not yet recruiting NCT06004817 - Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Recruiting NCT03324152 - Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT02043548 - Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Phase 2
Completed NCT03414086 - Predictor of Clinical Response to Acthar in Myositis
Completed NCT04628936 - Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. Phase 2
Recruiting NCT03293615 - Exercise Capacity of Patients With Dermatomyosis N/A
Completed NCT06002750 - Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation